# A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis

> **NCT03468556** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sinew Pharma Inc.** · enrollment: 80 (estimated)

## Conditions studied

- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** SNP-610
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03468556
- **Lead sponsor:** Sinew Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468556, "A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03468556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*